Developer docs
API playgroundTry for free, no card

Search company profiles

GenLives

Full company profile

uuid0023rv8

Namestring
GenLives
Legal namestring
GenLives
Websiteurl
genlives.com
Company typeenum
Private
Founded yearint
2016
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMontevideo, Uruguay
HQ citystring
Montevideo
HQ countrystring
Uruguay
HQ regionstring
Latin America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical genomic diagnostics, next generation sequencing, whole exome sequencing, hereditary cancer testing, precision genomic medicine
Industry4 codes
PRIMARYHLAFAMAH
Genetic & Prenatal Testing Laboratories
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAAANAA
Genomic Profiling & Sequencing-Based Precision Medicine
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code2 codes
  • Medical and Diagnostic Laboratories6215
  • Medical Laboratories621511
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Clinical Genomic Diagnostics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Genomic Testing Services
TypeOne Time License
Description

Clinical genomic testing services including whole exome sequencing, whole genome sequencing, and targeted gene panels for hereditary cancers, cardiomyopathies, neurology, and pre-reproduction. Revenue generated through individual test orders placed by physicians on the platform.

genlives.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

GenLives provides clinical genomic testing services in Uruguay using next-generation sequencing (NGS), including whole exome sequencing (~20,000 genes), whole genome sequencing (~3 billion bases), and targeted gene panels for hereditary cancers (BRCA1/2, colon), cardiomyopathies, neurology (Alzheimer, Parkinson), pre-reproduction carrier screening, and histamine intolerance (DAO). Studies are ordered exclusively through a physician-mediated platform and include pre- and post-study genetic counseling delivered by a multidisciplinary team of geneticists, bioinformaticians, and molecular biologists at no additional cost.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 8+ years average diagnostic delay in Latin America for genetic diseases can be reduced through early genomic testing
+2 more records
Product overview1 text field

GenLives is a precision genomic diagnostics company offering a unified portfolio of genomic studies for clinical use. The core products include Complete Exome (sequencing ~20,000 coding genes) and Complete Genome (sequencing ~3 billion DNA bases), supplemented by targeted add-on panels for specific conditions including hereditary cancers (breast cancer BRCA1/BRAC2, colon cancer), genetic cardiology (long/short QT, cardiomyopathies, Brugada), genetic neurology (Alzheimer, Parkinson), histamine intolerance (DAO), and pre-reproduction carrier screening. All studies are supported by a proprietary physician platform for online study requests, real-time tracking, and report access, plus included genetic counseling services provided by a multidisciplinary team of geneticists, bioinformaticians, and molecular biologists.

Product and service10 records
1Exoma Completo (Complete Exome)
CategoryClinical genomic test
Description

Sequencing of all protein-coding genes (~20,000 genes) providing a comprehensive view for differential diagnosis and diseases of unknown cause. Targeted at patients with rare or undiagnosed genetic conditions, ordered through their treating physician.

2Genoma Completo (Complete Genome)
CategoryClinical genomic test
Description

Whole genome sequencing of approximately 3 billion bases of human DNA, detecting any variant type in any genome region for the most powerful genomic diagnostic and prevention capability. Ordered through treating physicians for patients requiring comprehensive genomic analysis.

3Pre-Reproducción (Pre-Reproduction Carrier Screening)
CategoryTargeted genomic panel
Description

Study for couples planning to conceive that detects carrier status for recessive genetic diseases to support informed family planning. Ordered by physicians on behalf of couples.

4Cáncer de Mama (Hereditary Breast and Ovarian Cancer Panel)
CategoryTargeted genomic panel
Description

Analysis of BRCA1, BRCA2 and other susceptibility genes for hereditary breast and ovarian cancer. Ordered by physicians for patients with personal or family history suggesting hereditary cancer risk.

5Cáncer de Colon (Hereditary Colon Cancer Panel)
CategoryTargeted genomic panel
Description

Genetic analysis for hereditary colon cancer susceptibility. Ordered by physicians for patients with personal or family history suggesting hereditary colon cancer risk.

6Cardiopatías Genéticas (Genetic Cardiopathies Panel)
CategoryTargeted genomic panel
Description

Panels for hereditary cardiopathies including long/short QT, cardiomyopathies, arrhythmias, and Brugada syndrome. Ordered by cardiologists for patients with suspected inherited cardiovascular conditions.

7Neurología Genética - Alzheimer (Genetic Neurology – Alzheimer)
CategoryTargeted genomic panel
Description

Genetic predisposition study for Alzheimer disease, providing information for prevention and care planning. Ordered by physicians for at-risk patients.

8Neurología Genética - Parkinson (Genetic Neurology – Parkinson)
CategoryTargeted genomic panel
Description

Genetic predisposition study for Parkinson disease, providing information for prevention and care planning. Ordered by physicians for at-risk patients.

9Intolerancia Histamina DAO (Histamine Intolerance DAO Panel)
CategoryTargeted genomic panel
Description

Genetic analysis for histamine intolerance related to DAO (diamine oxidase) enzyme deficiency. Ordered by physicians for symptomatic patients.

10Asesoramiento Genético (Genetic Counseling)
CategoryClinical support service
Description

Pre- and post-study genetic counseling delivered by geneticists, bioinformaticians, and molecular biologists. Included at no additional cost with every GenLives genomic study to support patients and prescribing physicians in interpreting results.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Multiple team members hold positions at Institut Pasteur de Montevideo (Dra. Lucía Spangenberg as researcher, Dr. Hugo Naya as Head of Bioinformatics Unit and coordinator of URUGENOMES project, Lic. Daniela Megrián as bioinformatician). The institution provides research infrastructure and expertise supporting GenLives operations.

2UDELAR (Universidad de la República)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Dr. Víctor Raggio serves as Profesor Agregado de Genética Clínica at the Faculty of Medicine, UDELAR. Team members teach at UDELAR institutions, providing academic and research collaboration.

genlives.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Team members (Dra. Lucía Spangenberg and Lic. Daniela Megrián) serve as bioinformatics lecturers at Universidad ORT Uruguay, providing academic collaboration and talent development.

Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Italy-based whole-genome sequencing provider selling direct-to-consumer and clinical WGS with bioinformatics interpretation. Comparable technology stack (NGS WGS at scale) and variant interpretation pipeline, though distribution model differs.

TypeDirect peer
Description

Whole-genome sequencing company offering clinical and consumer genomics with integrated genetic counseling. Directly comparable technology portfolio (WGS, carrier screening, hereditary panels) and clinical interpretation emphasis.

TypeEmerging player
Description

India-headquartered genomics diagnostics company providing WES, WGS, and rare-disease panels with physician ordering workflow. Similar emerging-market positioning, multi-omic test menu, and focus on serving underserved populations in South Asia — a useful structural analog.

TypeBroad incumbent
Description

US-based genetic testing company offering reproductive, oncology, and hereditary panels with bioinformatics interpretation. Comparable clinical genetic testing capabilities but with broader reimbursement infrastructure and scaled sales coverage.

TypeBroad incumbent
Description

Large US-based clinical genetic testing laboratory (now part of Labcorp) offering broad hereditary panels, WES/WGS, and reproductive screening. Represents scaled competition with similar test menu and bioinformatics depth.

TypeBroad incumbent
Description

US consumer genomics company offering DTC genetic tests including health predisposition and carrier screening. Represents the consumer/D2C end of the genomic testing continuum; a potential distribution model alternative for GenLives.

TypeDirect peer
Description

Germany-based rare disease diagnostics laboratory providing whole-exome, whole-genome, and targeted panels with integrated genetic interpretation. Directly comparable focus on rare-disease diagnostic odyssey, multi-database annotation, and physician-mediated clinical reporting.

TypeDirect peer
Description

Brazilian clinical genomics laboratory offering exome, genome, and hereditary cancer panels with physician-mediated ordering. Closest regional peer given geographic adjacency, language overlap, and similar B2B2C clinical model in Latin America.

TypeBroad incumbent
Description

US preventive genomics company offering hereditary cancer, cardiovascular, and pharmacogenomic panels with integrated counseling. Comparable focus on hereditary cancer (BRCA) and cardiac panels, scaled via employer and provider partnerships.

TypeEmerging player
Description

India-based preventive and clinical genomics company offering whole-genome, hereditary panels, and pharmacogenomics with genetic counseling. Comparable portfolio breadth (WGS + targeted panels + counseling), with physician-mediated and consumer channels.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

GenLives

Clinical Genomic Diagnosticsgenlives.com

GenLives firmographics

Firmographics
Name
GenLives
Legal name
GenLives
Website
https://genlives.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

GenLives industry classification

Industry
Product category
Clinical Genomic Diagnostics
NAICS
Medical and Diagnostic Laboratories (6215), Medical Laboratories (621511)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAFAMAH
Genetic & Prenatal Testing Laboratories
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAAANAA
Genomic Profiling & Sequencing-Based Precision Medicine
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Clinical genomic diagnostics
  • Next generation sequencing
  • Whole exome sequencing
  • Hereditary cancer testing
  • Precision genomic medicine

Where GenLives is headquartered

Location

Headquarters

HQ city
Montevideo
HQ country
Uruguay
HQ region
Latin America

Offices2 records

Markets served

GenLives business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Genomic Testing Services: Clinical genomic testing services including whole exome sequencing, whole genome sequencing, and targeted gene panels for hereditary cancers, cardiomyopathies, neurology, and pre-reproduction. Revenue generated through individual test orders placed by physicians on the platform.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

GenLives product offering

Product offering

Core offering

GenLives provides clinical genomic testing services in Uruguay using next-generation sequencing (NGS), including whole exome sequencing (~20,000 genes), whole genome sequencing (~3 billion bases), and targeted gene panels for hereditary cancers (BRCA1/2, colon), cardiomyopathies, neurology (Alzheimer, Parkinson), pre-reproduction carrier screening, and histamine intolerance (DAO). Studies are ordered exclusively through a physician-mediated platform and include pre- and post-study genetic counseling delivered by a multidisciplinary team of geneticists, bioinformaticians, and molecular biologists at no additional cost.

Product overview

GenLives is a precision genomic diagnostics company offering a unified portfolio of genomic studies for clinical use. The core products include Complete Exome (sequencing ~20,000 coding genes) and Complete Genome (sequencing ~3 billion DNA bases), supplemented by targeted add-on panels for specific conditions including hereditary cancers (breast cancer BRCA1/BRAC2, colon cancer), genetic cardiology (long/short QT, cardiomyopathies, Brugada), genetic neurology (Alzheimer, Parkinson), histamine intolerance (DAO), and pre-reproduction carrier screening. All studies are supported by a proprietary physician platform for online study requests, real-time tracking, and report access, plus included genetic counseling services provided by a multidisciplinary team of geneticists, bioinformaticians, and molecular biologists.

Differentiator

Problem solved

Functional benefit

Products and services

  • Exoma Completo (Complete Exome) Sequencing of all protein-coding genes (~20,000 genes) providing a comprehensive view for differential diagnosis and diseases of unknown cause. Targeted at patients with rare or undiagnosed genetic conditions, ordered through their treating physician.
  • Genoma Completo (Complete Genome) Whole genome sequencing of approximately 3 billion bases of human DNA, detecting any variant type in any genome region for the most powerful genomic diagnostic and prevention capability. Ordered through treating physicians for patients requiring comprehensive genomic analysis.
  • Pre-Reproducción (Pre-Reproduction Carrier Screening) Study for couples planning to conceive that detects carrier status for recessive genetic diseases to support informed family planning. Ordered by physicians on behalf of couples.
  • Cáncer de Mama (Hereditary Breast and Ovarian Cancer Panel) Analysis of BRCA1, BRCA2 and other susceptibility genes for hereditary breast and ovarian cancer. Ordered by physicians for patients with personal or family history suggesting hereditary cancer risk.
  • Cáncer de Colon (Hereditary Colon Cancer Panel) Genetic analysis for hereditary colon cancer susceptibility. Ordered by physicians for patients with personal or family history suggesting hereditary colon cancer risk.
  • Cardiopatías Genéticas (Genetic Cardiopathies Panel) Panels for hereditary cardiopathies including long/short QT, cardiomyopathies, arrhythmias, and Brugada syndrome. Ordered by cardiologists for patients with suspected inherited cardiovascular conditions.
  • Neurología Genética - Alzheimer (Genetic Neurology – Alzheimer) Genetic predisposition study for Alzheimer disease, providing information for prevention and care planning. Ordered by physicians for at-risk patients.
  • Neurología Genética - Parkinson (Genetic Neurology – Parkinson) Genetic predisposition study for Parkinson disease, providing information for prevention and care planning. Ordered by physicians for at-risk patients.
  • Intolerancia Histamina DAO (Histamine Intolerance DAO Panel) Genetic analysis for histamine intolerance related to DAO (diamine oxidase) enzyme deficiency. Ordered by physicians for symptomatic patients.
  • Asesoramiento Genético (Genetic Counseling) Pre- and post-study genetic counseling delivered by geneticists, bioinformaticians, and molecular biologists. Included at no additional cost with every GenLives genomic study to support patients and prescribing physicians in interpreting results.

Quantifiable outcome

  • 8+ years average diagnostic delay in Latin America for genetic diseases can be reduced through early genomic testing
  • +2 more outcomes

Companies that use GenLives

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles2 records

GenLives technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

GenLives partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Institut Pasteur de MontevideocoreStrategic or Co-development PartnerMultiple team members hold positions at Institut Pasteur de Montevideo (Dra. Lucía Spangenberg as researcher, Dr. Hugo Naya as Head of Bioinformatics Unit and coordinator of URUGENOMES project, Lic. Daniela Megrián as bioinformatician). The institution provides research infrastructure and expertise supporting GenLives operations.
  • UDELAR (Universidad de la República)minorStrategic or Co-development PartnerDr. Víctor Raggio serves as Profesor Agregado de Genética Clínica at the Faculty of Medicine, UDELAR. Team members teach at UDELAR institutions, providing academic and research collaboration.
  • Universidad ORT UruguayminorStrategic or Co-development PartnerTeam members (Dra. Lucía Spangenberg and Lic. Daniela Megrián) serve as bioinformatics lecturers at Universidad ORT Uruguay, providing academic collaboration and talent development.

Scale indicators6 records

Recent moves1 record

Expansion highlights4 records

GenLives competitors and assessment

Company assessment

Direct peers

  • Dante Labs: Italy-based whole-genome sequencing provider selling direct-to-consumer and clinical WGS with bioinformatics interpretation. Comparable technology stack (NGS WGS at scale) and variant interpretation pipeline, though distribution model differs.
  • Veritas Genetics: Whole-genome sequencing company offering clinical and consumer genomics with integrated genetic counseling. Directly comparable technology portfolio (WGS, carrier screening, hereditary panels) and clinical interpretation emphasis.
  • Centogene: Germany-based rare disease diagnostics laboratory providing whole-exome, whole-genome, and targeted panels with integrated genetic interpretation. Directly comparable focus on rare-disease diagnostic odyssey, multi-database annotation, and physician-mediated clinical reporting.
  • Mendelics: Brazilian clinical genomics laboratory offering exome, genome, and hereditary cancer panels with physician-mediated ordering. Closest regional peer given geographic adjacency, language overlap, and similar B2B2C clinical model in Latin America.

Emerging players

  • MedGenome: India-headquartered genomics diagnostics company providing WES, WGS, and rare-disease panels with physician ordering workflow. Similar emerging-market positioning, multi-omic test menu, and focus on serving underserved populations in South Asia — a useful structural analog.
  • Mapmygenome: India-based preventive and clinical genomics company offering whole-genome, hereditary panels, and pharmacogenomics with genetic counseling. Comparable portfolio breadth (WGS + targeted panels + counseling), with physician-mediated and consumer channels.

Broad incumbents

  • Natera: US-based genetic testing company offering reproductive, oncology, and hereditary panels with bioinformatics interpretation. Comparable clinical genetic testing capabilities but with broader reimbursement infrastructure and scaled sales coverage.
  • Invitae (Labcorp Genetics): Large US-based clinical genetic testing laboratory (now part of Labcorp) offering broad hereditary panels, WES/WGS, and reproductive screening. Represents scaled competition with similar test menu and bioinformatics depth.
  • 23andMe: US consumer genomics company offering DTC genetic tests including health predisposition and carrier screening. Represents the consumer/D2C end of the genomic testing continuum; a potential distribution model alternative for GenLives.
  • Color Genomics: US preventive genomics company offering hereditary cancer, cardiovascular, and pharmacogenomic panels with integrated counseling. Comparable focus on hereditary cancer (BRCA) and cardiac panels, scaled via employer and provider partnerships.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

GenLives social profiles

Digital presence

GenLives compliance and trust

Trust signal

Compliance1 record

GenLives financial estimates

Financial estimate

Revenue estimate

Valuation estimate

GenLives leadership team

Management profile

Number of profiles

Profiles7 records

GenLives funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

GenLives M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GenLives

What does GenLives do?

GenLives provides clinical genomic testing services in Uruguay using next-generation sequencing (NGS), including whole exome sequencing (~20,000 genes), whole genome sequencing (~3 billion bases), and targeted gene panels for hereditary cancers (BRCA1/2, colon), cardiomyopathies, neurology (Alzheimer, Parkinson), pre-reproduction carrier screening, and histamine intolerance (DAO). Studies are ordered exclusively through a physician-mediated platform and include pre- and post-study genetic counseling delivered by a multidisciplinary team of geneticists, bioinformaticians, and molecular biologists at no additional cost.

Is GenLives a public or private company?

GenLives is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was GenLives founded?

GenLives was founded in 2016. It employs 1 to 10 people.

Where is GenLives based?

GenLives is headquartered in Montevideo, Uruguay, in the Latin America region.

How does GenLives make money?

One revenue line is on record: genomic Testing Services.

Who are GenLives's main competitors?

Direct peers on record are Dante Labs, Veritas Genetics, Centogene and Mendelics. Emerging players are MedGenome and Mapmygenome. Broad incumbents are Natera, Invitae (Labcorp Genetics), 23andMe and Color Genomics.

Does GenLives have an API?

No public API is recorded for GenLives.

What industry is GenLives in?

GenLives's product category is Clinical Genomic Diagnostics. Its primary akta.pro industry code is HLAFAMAH, Genetic & Prenatal Testing Laboratories, with a secondary code of HLAFAMAE, Molecular Diagnostics & Genomics Laboratories. Its NAICS code is 6215 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales